Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
复制标题
DOI：
10.1212/01.wnl.0000223844.77636.29
复制
发表时间：
2006-07-11
期刊：
影响因子：
9.9
通讯作者：
Wen, P. Y.
中科院分区：
文献类型：
--
作者：
Doherty, L.;Gigas, D. C.;Wen, P. Y.
恶性胶质瘤的特征通常是表皮生长因子受体（EGFR）的扩增和PTEN肿瘤抑制基因的缺失。28名接受过大量预治疗的复发性恶性胶质瘤患者接受了EGFR抑制剂（吉非替尼或厄洛替尼）与mTOR（哺乳动物雷帕霉素靶点）抑制剂西罗莫司联合给药。这些方案耐受性良好。19%的患者出现部分缓解，50%的患者病情稳定。胶质母细胞瘤患者的6个月无进展生存率为25%。
Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor ( EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR ( mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.